Intervention with WhatsApp Messaging to Assess the Effect of Self-designed Messages and Standardized Messages in Adherence to Antiretroviral Treatment in Young People Living with HIV in a Hospital in Lima, Peru: Randomized Control Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- HIV
- Sponsor
- Universidad Peruana Cayetano Heredia
- Enrollment
- 131
- Locations
- 1
- Primary Endpoint
- Change from Baseline in the Result of SMAQ Questionnaire Adjusted for the Effect of Covariables
- Status
- Active, Not Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this clinical trial is to learn which type of messages is more efficacious to improve adherence to medication in young people living with HIV. The main question is aims to answer is:
-Are messages designed by participants (self-designed) more efficacious than messages designed by health providers to improve adherence to antiretroviral treatment (HIV medications)?
Researchers will compare both types of messages to see if one is better than the other in helping participants take their medications.
Participants will:
- Receive either messages designed by themselves or by health providers for 4 months.
- Be able to chat with health providers at any time, with special focus regarding questions about their condition, medications and health services.
- Complete questionnaires via WhatsApp describing how they are taking their medications, and how often they forget to take them.
- Complete questionnaires via WhatsApp describing their opinion about receiving the messages and being able to chat with health providers.
Investigators
Jeffrey Freidenson
Principal Investigator
Universidad Peruana Cayetano Heredia
Eligibility Criteria
Inclusion Criteria
- •People living with HIV of age 18-29 at the moment of signing informed consent.
- •Being a patient of the study center's Infectious Diseases clinic or National HIV Program, between March 2024 and July
- •Ownership of a mobile phone that supports WhatsApp.
Exclusion Criteria
- •Being pregnant at the moment of signing informed consent.
- •Being illiterate at the moment of signing informed consent.
- •Being blind at the moment of signing informed consent
Outcomes
Primary Outcomes
Change from Baseline in the Result of SMAQ Questionnaire Adjusted for the Effect of Covariables
Time Frame: Baseline, 16 weeks.
The SMAQ questionnaire evaluates medication adherence. It provides a dichotomic result of adherence (yes/no), and a semiquantitative estimate of adherence. Greater than 95% adherence is considered as adherent, and less than 95% as non-adherent.
Secondary Outcomes
- ART adherence measured by SMAQ Questionnaire at 4, 8 and 12 weeks of intervention(4, 8 and 12 weeks of intervention)
- Loss to follow-up(From the start of delivery intervention until study completion)
- Metrics on the use of a bidirectional platform for intervention delivery(End of the intervention at 16 weeks.)
- Time of permanence in the study(Baseline until study completion (16 weeks).)